These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34118485)

  • 1. Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil.
    Kelly DL; Claxton A; Bidollari I; Du Y
    Psychiatry Res; 2021 Aug; 302():114030. PubMed ID: 34118485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels.
    Tasaki M; Yasui-Furukori N; Yokoyama S; Shinozaki M; Sugawara N; Shimoda K
    Neuropsychopharmacol Rep; 2021 Sep; 41(3):379-384. PubMed ID: 34189861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective analysis of serum prolactin levels, clinical symptomatology and sexual functions in patients with schizophrenia switched to paliperidone palmitate 3-monthly from paliperidone palmitate 1-monthly: Preliminary findings of the first 3 months.
    Karslioğlu EH; Kolcu Z; Karslioğlu Nİ; Çayköylü A
    Hum Psychopharmacol; 2022 May; 37(3):e2827. PubMed ID: 34787912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.
    Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Steen Andersen H; Eramo A; Hansen K; Naber D
    Int Clin Psychopharmacol; 2017 May; 32(3):147-154. PubMed ID: 28252452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study.
    Gopal S; Lane R; Nuamah I; Copenhaver M; Singh J; Hough D; Bach M; Savitz A
    CNS Drugs; 2017 Sep; 31(9):797-808. PubMed ID: 28660406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study.
    Miller BJ; Claxton A; Du Y; Weiden PJ; Potkin SG
    Schizophr Res; 2019 Jun; 208():44-48. PubMed ID: 30745067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
    Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
    Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.
    Qiao Y; Yang F; Li C; Guo Q; Wen H; Zhu S; Ouyang Q; Shen W; Sheng J
    Psychiatry Res; 2016 Mar; 237():83-9. PubMed ID: 26921057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents.
    Krøigaard SM; Clemmensen L; Tarp S; Pagsberg AK
    J Child Adolesc Psychopharmacol; 2022 Sep; 32(7):374-389. PubMed ID: 36074098
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study.
    Yoon HW; Lee JS; Park SJ; Lee SK; Choi WJ; Kim TY; Hong CH; Seok JH; Park IH; Son SJ; Roh D; Kim BR; Lee BO
    Clin Neuropharmacol; 2016; 39(6):288-294. PubMed ID: 27438182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
    Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
    Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
    Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R
    Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs.
    Kucka M; Tomić M; Bjelobaba I; Stojilkovic SS; Budimirovic DB
    Sci Rep; 2015 Mar; 5():8902. PubMed ID: 25754735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D
    Düring SW; Nielsen MØ; Bak N; Glenthøj BY; Ebdrup BH
    Psychiatry Res; 2019 Apr; 274():58-65. PubMed ID: 30780063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate.
    Montalvo I; Ortega L; López X; Solé M; Monseny R; Franch J; Vilella E; Labad J
    Int Clin Psychopharmacol; 2013 Jan; 28(1):46-9. PubMed ID: 23232756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
    Weiden PJ; Du Y; Liu CC; Stanford AD
    CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
    Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: A preliminary study.
    Park YM; Lee SH; Lee BH; Lee KY; Lee KS; Kang SG; Lee HY; Kim W
    Psychiatry Res; 2016 May; 239():184-9. PubMed ID: 27010188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.